Gilead Sciences, Inc. (GILD) Holdings Reduced by Alliancebernstein L.P.
Alliancebernstein L.P. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,936,564 shares of the biopharmaceutical company’s stock after selling 559,878 shares during the period. Gilead Sciences accounts for about 0.6% of Alliancebernstein L.P.’s holdings, making the stock its 26th largest holding. Alliancebernstein L.P. owned about 0.84% of Gilead Sciences worth $774,090,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. raised its position in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the last quarter. Penserra Capital Management LLC raised its position in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the last quarter. American Beacon Advisors Inc. bought a new position in Gilead Sciences during the 1st quarter valued at approximately $143,000. Sterling Investment Advisors Ltd. bought a new position in Gilead Sciences during the 2nd quarter valued at approximately $184,000. Finally, Washington Trust Bank raised its position in Gilead Sciences by 24.8% during the 2nd quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 550 shares during the last quarter. 74.62% of the stock is owned by institutional investors and hedge funds.
In related news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 666,819 shares of company stock worth $52,303,086. 1.30% of the stock is owned by insiders.
Gilead Sciences, Inc. (GILD) opened at $71.81 on Thursday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The stock has a market capitalization of $92,941.05, a price-to-earnings ratio of 7.43, a PEG ratio of -1.19 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same period last year, the firm earned $2.75 EPS. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.90%. Gilead Sciences’s dividend payout ratio is currently 23.69%.
TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Holdings Reduced by Alliancebernstein L.P.” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/16/gilead-sciences-inc-gild-holdings-reduced-by-alliancebernstein-l-p.html.
Several research analysts have recently issued reports on GILD shares. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 2nd. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research report on Friday, July 28th. Redburn Partners started coverage on Gilead Sciences in a research report on Wednesday, July 26th. They issued a “buy” rating for the company. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $84.87.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.